Clinical trial
A Phase II Study of Durvalumab (MEDI 4736) Maintenance in Frail Limited Disease Small Cell Lung Cancer Patients After Thoracic Chemoradiotherapy (CRT)
NCT05617963 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Durvalumab (MEDI 4736) Maintenance in Frail Limited Disease Small Cell Lung Cancer Patients After Thoracic Chemoradiotherapy (CRT)
- Lead sponsor
- UNICANCER
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- March 24, 2023
- Completion date
- February 24, 2030
- Enrollment
- 100 (estimated)
- Sites
- 32
Conditions
As the registry lists them; a condition with its own page is linked.